miR-10b-5p 改善糖尿病及胃肠动力障碍
研究揭示 miR-10b-5p 在糖尿病小鼠 ICC 中显著耗竭,其通过 KLF11-KIT 通路调控 β 细胞和 ICC 存活;在多种糖尿病小鼠模型中注射 miR-10b-5p 模拟物可长期改善糖尿病和胃轻瘫表型,且效果优于常用降糖药和促动力药。
要点
- miR-10b-5p 在糖尿病小鼠 ICC 中显著下调,与胃轻瘫发生相关。
- miR-10b-5p 通过靶向 KLF11 负调控 KIT 表达,维持 ICC 和 β 细胞功能。
- miR-10b-5p 模拟物改善糖尿病小鼠的血糖稳态和胃肠动力,效果优于对照药物。
核心结论
- miR-10b-5p 是糖尿病和胃肠动力障碍的关键调控因子,恢复其表达可能为治疗提供获益。
研究设计与样本
- 对糖尿病小鼠分离的 ICC 及特发性和糖尿病胃轻瘫患者血浆进行 miRNA 测序分析。
- 使用 KIT+ 细胞特异性 mir-10b 敲除小鼠和 KIT+ 细胞清除小鼠进行功能缺失研究。
- 在多种糖尿病小鼠模型中注射合成 miR-10b-5p 模拟物进行功能获得研究,并与降糖药和促动力药比较疗效。
主要发现
- miR-10b-5p 在健康小鼠 ICC 中高表达,但在糖尿病小鼠 ICC 中急剧耗竭。
- KIT+ 细胞中条件性敲除 mir-10b 或清除 KIT+ 细胞导致 β 细胞和 ICC 退化,引起糖尿病和胃轻瘫。
- miR-10b-5p 靶向转录因子 KLF11,后者负调控 KIT 表达。
- 注射 miR-10b-5p 模拟物或 Klf11 siRNA 可长期挽救 mir-10b 敲除、饮食诱导糖尿病和 TALLYHO 多基因糖尿病小鼠的糖尿病和胃轻瘫表型。
- miR-10b-5p 模拟物在改善血糖稳态和胃肠动力方面比常用降糖药和促动力药更有效。
临床怎么用
- miR-10b-5p 模拟物可能作为糖尿病和胃轻瘫的潜在治疗策略,但尚未进入临床验证。
局限性
- 研究主要基于小鼠模型和细胞系,人体内疗效和安全性尚未确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Interstitial cells of Cajal (ICCs) and pancreatic β cells require receptor tyrosine kinase (KIT) to develop and function properly. Degeneration of ICCs is linked to diabetic gastroparesis. The mechanisms linking diabetes and gastroparesis are unclear, but may involve microRNA (miRNA)-mediated post-transcriptional gene silencing in KIT+ cells. METHODS: We performed miRNA-sequencing analysis from isolated ICCs in diabetic mice and plasma from patients with idiopathic and diabetic gastroparesis. miR-10b-5p target genes were identified and validated in mouse and human cell lines. For loss-of-function studies, we used KIT+ cell-restricted mir-10b knockout mice and KIT+ cell depletion mice. For gain-of-function studies, a synthetic miR-10b-5p mimic was injected in multiple diabetic mouse models. We compared the efficacy of miR-10b-5p mimic treatment vs antidiabetic and prokinetic medicines. RESULTS: miR-10b-5p is highly expressed in ICCs from healthy mice, but drastically depleted in ICCs from diabetic mice. A conditional knockout of mir-10b in KIT+ cells or depletion of KIT+ cells in mice leads to degeneration of β cells and ICCs, resulting in diabetes and gastroparesis. miR-10b-5p targets the transcription factor Krüppel-like factor 11 (KLF11), which negatively regulates KIT expression. The miR-10b-5p mimic or Klf11 small interfering RNAs injected into mir-10b knockout mice, diet-induced diabetic mice, and TALLYHO polygenic diabetic mice rescue the diabetes and gastroparesis phenotype for an extended period of time. Furthermore, the miR-10b-5p mimic is more effective in improving glucose homoeostasis and gastrointestinal motility compared with common antidiabetic and prokinetic medications. CONCLUSIONS: miR-10b-5p is a key regulator in diabetes and gastrointestinal dysmotility via the KLF11-KIT pathway. Restoration of miR-10b-5p may provide therapeutic benefits for these disorders.
引用
- Singh R, Ha SE, Wei L, et al. miR-10b-5p Rescues Diabetes and Gastrointestinal Dysmotility. Gastroenterology. 2021. PMID: 33421511. doi:10.1053/j.gastro.2020.12.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。